Ieq Capital LLC Purchases Shares of 13,757 TG Therapeutics, Inc. $TGTX

Ieq Capital LLC purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the second quarter, Holdings Channel.com reports. The firm purchased 13,757 shares of the biopharmaceutical company’s stock, valued at approximately $756,000.

Other large investors also recently modified their holdings of the company. Danske Bank A S acquired a new position in shares of TG Therapeutics during the 3rd quarter valued at $25,000. EverSource Wealth Advisors LLC grew its holdings in TG Therapeutics by 51.9% in the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 365 shares during the period. Hantz Financial Services Inc. grew its holdings in TG Therapeutics by 82.7% in the fourth quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 560 shares during the period. Truvestments Capital LLC increased its stake in TG Therapeutics by 172.4% in the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 1,026 shares in the last quarter. Finally, Kemnay Advisory Services Inc. bought a new stake in TG Therapeutics in the fourth quarter valued at $52,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on TGTX. HC Wainwright reissued a “buy” rating and set a $78.00 price objective on shares of TG Therapeutics in a research report on Tuesday, August 4th. JPMorgan Chase & Co. boosted their target price on TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Jefferies Financial Group reaffirmed a “buy” rating and set a $83.00 price target on shares of TG Therapeutics in a research note on Monday, June 22nd. B. Riley Financial increased their price target on TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a report on Monday, July 27th. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a research report on Wednesday, July 29th. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $63.00.

TG Therapeutics Trading Up 1.3%

NASDAQ:TGTX opened at $55.72 on Friday. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.27 and a quick ratio of 3.72. TG Therapeutics, Inc. has a one year low of $26.76 and a one year high of $59.30. The company has a market cap of $8.53 billion, a PE ratio of 20.34, a PEG ratio of 2.36 and a beta of 1.62. The firm has a 50-day moving average of $53.36 and a 200-day moving average of $41.74.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.26). The business had revenue of $240.34 million during the quarter, compared to the consensus estimate of $229.77 million. TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. TG Therapeutics’s revenue was up 70.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.17 EPS. As a group, equities research analysts expect that TG Therapeutics, Inc. will post 0.92 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.